ImevaX’ pipeline focuses on three main products: the vaccine IMX101, the mucosal adjuvant CTA, and a rapid diagnostic test for Helicobacter pylori.

ImevaX' current pipeline.

  • IMX101: The first immune evasion vaccine against Helicobacter pylori

  • IMA101 and 102: a mucosal adjuvant that is tested in the clinical phase I trial for the first time.

  • IMD101: The first rapid test that is diagnosing Helicobacter pylori infection and pathogenicity at the same time.